Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

    2026-05-14

    Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights and Experimental Considerations

    Study Background and Research Question

    The renin–angiotensin–aldosterone system (RAAS) is a central regulator of cardiovascular, renal, and endocrine physiology, with angiotensin peptides orchestrating critical signaling events through AT1 and AT2 receptors. While the classical function of these peptides—including Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe)—in blood pressure regulation and aldosterone secretion is well established (source: internal_article), their potential roles in modulating viral pathogenesis have only recently been explored. The emergence of SARS-CoV-2 has prompted investigation into how endogenous peptides may influence viral entry, particularly via non-canonical receptors such as AXL, which is implicated in infection of cells with low ACE2 expression. This study by Oliveira et al. addresses a critical question: Do angiotensin-derived peptides alter the binding affinity of the SARS-CoV-2 spike protein for its cellular receptors, and if so, which peptide sequences and modifications are most influential (source: paper)?

    Key Innovation from the Reference Study

    The central innovation lies in the identification of naturally occurring angiotensin peptide fragments—particularly those generated by N-terminal cleavage, such as Angiotensin III and Angiotensin IV—that enhance the interaction between the SARS-CoV-2 spike protein and the AXL receptor. Notably, this effect is not uniform across all angiotensin derivatives: the parent peptide angiotensin II increases spike–AXL binding twofold, whereas N-terminal truncations, including Angiotensin III (2–8), result in even greater enhancement (source: paper). This mechanistic link between RAAS peptides and viral entry receptor engagement represents a paradigm shift, suggesting endogenous cardiovascular peptides may contribute to viral infectivity and tropism, especially in tissues with variable ACE2 expression.

    Methods and Experimental Design Insights

    The authors employed antibody-based binding assays to quantitatively assess the interaction between the SARS-CoV-2 spike protein and three cellular receptors: ACE2, NRP1, and AXL. A range of angiotensin peptides—spanning full-length angiotensin I and II, as well as progressively truncated N- and C-terminal fragments—were synthesized and tested for their ability to modulate these interactions. Key design features include:
    • Use of recombinant spike proteins and purified receptor proteins to isolate direct binding effects.
    • Systematic comparison of full-length versus truncated peptides, enabling structure–activity relationship (SAR) analysis.
    • Inclusion of peptides with specific residue modifications (e.g., tyrosine phosphorylation or substitution) to probe the role of side chain chemistry in receptor modulation.
    These approaches allowed for a nuanced mapping of how angiotensin sequence variants—and their biochemical modifications—influence viral spike–receptor engagement.

    Core Findings and Why They Matter

    The primary findings can be summarized as follows:
    • Angiotensin II (1–8) increases spike–AXL binding by approximately twofold, but has minimal influence on spike–ACE2 or spike–NRP1 interactions (source: paper).
    • N-terminally truncated peptides—notably Angiotensin III (2–8) and Angiotensin IV (3–8)—are even more potent, with Angiotensin IV producing a 2.7-fold increase in spike–AXL binding (source: paper).
    • C-terminal truncations (e.g., angiotensin (1–7), angiotensin (1–6)) can enhance spike–AXL binding but do not exceed the activity of N-terminally truncated forms.
    • Residue modifications at tyrosine (position 4)—either substitution or phosphorylation—amplify the spike–AXL interaction, highlighting structure–function relationships relevant for receptor ligand design.
    The discovery that Angiotensin III, a peptide best known as an aldosterone secretion inducer and pressor activity mediator (source: internal_article), can potentiate viral spike–AXL binding, underscores the need to consider cardiovascular peptides not only as homeostatic regulators but also as potential modulators of viral pathogenesis.

    Comparison with Existing Internal Articles

    Several internal resources have previously addressed the multifaceted functions of Angiotensin III in cardiovascular and neuroendocrine research: These articles collectively frame Angiotensin III as a cardiovascular research peptide with growing relevance in infectious disease modeling, as now substantiated by the reference study’s findings.

    Limitations and Transferability

    Despite its significant mechanistic insights, the study is subject to several limitations:
    • In vitro system constraints: The binding assays were performed using purified proteins and do not capture the full complexity of cellular or tissue-level interactions, nor do they account for in vivo peptide concentrations or metabolic stability (source: paper).
    • Specificity for AXL: The enhancement of spike–AXL binding was more pronounced than for ACE2 or NRP1, but the physiological consequences of this enhancement in intact organisms remain to be fully established.
    • Translational maturity: While the findings raise important hypotheses about endogenous peptide modulation of viral infection and tissue tropism, direct clinical implications require further validation.

    Protocol Parameters

    • binding assay | 2-fold enhancement in spike–AXL binding (Angiotensin II) | in vitro receptor–ligand binding | Demonstrates functional modulation by angiotensin peptides | paper
    • binding assay | 2.7-fold enhancement in spike–AXL binding (Angiotensin IV) | in vitro receptor–ligand binding | Identifies most potent truncated peptide in the series | paper
    • peptide solubility | ≥23.2 mg/mL (water), ≥43.8 mg/mL (ethanol), ≥93.1 mg/mL (DMSO) | peptide solution preparation | Ensures efficient assay setup and reproducibility | product_spec
    • storage condition | desiccated at -20°C | peptide stability for repeated assays | Prevents degradation and maintains activity | product_spec
    • peptide purity | 98.97% (HPLC) | assay reliability | Minimizes off-target effects and batch variability | product_spec
    • binding assay | 1 μM–10 μM peptide concentration (workflow recommendation) | receptor binding modulation | Reported as a practical range in similar studies; actual optimal value should be empirically determined | workflow_recommendation

    Why this cross-domain matters, maturity, and limitations

    The bridge between cardiovascular RAAS peptides and viral entry mechanisms is supported by direct experimental evidence in the reference study. This cross-domain insight is particularly relevant for modeling SARS-CoV-2 tissue tropism and for understanding how host peptide milieu may influence infection risk or severity in cardiovascular patients. However, the translational maturity remains at the preclinical stage; further studies are required to define the in vivo relevance and therapeutic implications of these findings (source: paper).

    Research Support Resources

    Researchers seeking to replicate or extend these findings can utilize Angiotensin III (human, mouse) (SKU A1043) from APExBIO, which offers high purity and validated solubility for binding, receptor profiling, or functional assays. The workflow-optimized formulation and comprehensive quality controls align with the rigorous standards required for both RAAS and viral entry research (source: internal_article; product_spec).